Company / Return on Equity (ROE)
ResMed Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
23.5%
FY2025
5-year range
16.4% / 23.5%
FY2021-FY2025
Trend
+11.8%
vs FY2024
Sector context
#14 of 147
Health Care
What the data says
Among 147 Health Care companies, ResMed is in the top 10% for return on equity (roe). Return on Equity (ROE) returned to growth in FY2025 after 2 years of decline, reaching 23.5%.
Based on SEC 10-K filings.
23.5% in FY2025 with a 5-year CAGR of -1.4%. Top quartile in the Health Care sector.
Improved from 21.7% to 23.5% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +0.3pp
- 5-Year Change
- -1.4pp
- 10-Year Change
- -
Sector benchmark
Top 10% in Health CareTop 10% of 147This company 23.5% Sector average -3.1%
▼
+852.1% above sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 11.8% year-over-year.
- Currently 26.6pp above the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2020.
- Lowest return on equity (roe) in the period was in FY2018.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 3.25 (safe zone, above 2.9 threshold)
- Strong profit margin: 27.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 23.5% | +11.8% |
| FY2024 | 21.0% | -3.4% |
| FY2023 | 21.7% | -6.3% |
| FY2022 | 23.2% | +41.1% |
| FY2021 | 16.4% | -34.0% |
| FY2020 | 24.9% | +27.6% |
| FY2019 | 19.5% | +27.3% |
| FY2018 | 15.3% | -12.2% |
| FY2017 | 17.5% | -16.0% |
| FY2016 | 20.8% | -6.5% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026